

## SUPPLEMENTAL TABLES

Table 1S. Relative risk of ovarian cancer in users of different hormonal contraceptive products during follow-up (full cohort). Never use as reference.

	Person-years	Cancer events	Adjusted* Relative Risk (95% confidence interval)
<u>Current or recent use of combined hormonal contraception:</u>			
<b>Oral</b>			
Norethisterone 50µg EE†	57,516	4	0.96 (0.36-2.56)
Levonorgestrel 50µg EE	82,756	9	1.26 (0.65-2.43)
Norethisterone 30-35µg EE	165,211	8	0.99 (0.49-2.01)
Levonorgestrel 30-35 µg EE	1,016,015	23	0.43 (0.28-0.65)
Desogestrel 20-30 µg EE	1,659,258	31	0.46 (0.32-0.66)
Gestodene 20-35 µg EE	2,985,909	58	0.48 (0.36-0.63)
Drospirenone 20-35 µg EE	592,556	13	0.65 (0.37-1.15)
Norgestimate 35 µg EE	721,004	19	0.64 (0.40-1.01)
Cyproterone 30 µg EE	317,961	6	0.48 (0.21-1.07)
Estradiol valerate, dienogest	14,081	0	-
<b>Non-oral</b>			
Patch	15,358	0	-
Vaginal ring	124,280	4	0.93 (0.35-2.52)
<u>Current or recent use of progestogen-only:</u>			
<b>Oral</b>			
Norethisterone	158,073	7	0.62 (0.29-1.30)
Levonorgestrel	11,544	2	1.65 (0.41-6.62)
Desogestrel	123,539	2	0.33 (0.08-1.32)
<b>Non-oral</b>			
MPA depot	27,832	3	2.62 (0.84-8.17)
Implant	58,371	1	0.51 (0.07-3.64)
LNG-IUS	708,111	44	0.72 (0.53-0.99)

\*Adjusted for: calendar year, parity, age, education, tubal sterilisation, hysterectomy, endometriosis, polycystic ovary syndrome and family history of breast or ovarian cancer.

†Ethinylestradiol

Table 2S. Relative risk of ovarian cancer in users of different hormonal contraceptive products in women aged 15 on or after 1<sup>st</sup> January 1995 (full hormonal contraceptive history).

	Person-years	Cancer events	Adjusted* Relative Risk (95% confidence interval)
Never Use	1,570,546	21	1.00
Ever use (any hormonal contraception)	3,846,722	56	0.65 (0.36-1.18)
Former use (any hormonal)	593,309	14	0.93 (0.41-2.10)
Current or recent use (any hormonal)	3,253,413	42	0.61 (0.33-1.13)
<u>Current or recent use combined hormonal contraception:</u>			
<u>Oral</u>			
Norethisterone 50µg EE†	2,656	0	-
Levonorgestrel 50µg EE	7,344	0	-
Norethisterone 30-35µg EE	19,361	1	2.73 (0.35-21.30)
Levonorgestrel 30-35 µg EE	391,616	6	0.84 (0.30-2.32)
Desogestrel 20-30 µg EE	675,407	11	0.77 (0.35-1.70)
Gestodene 20-35 µg EE	1,119,559	12	0.50 (0.23-1.09)
Drospirenone 20-35 µg EE	367,906	4	0.52 (0.17-1.59)
Norgestimate 35 µg EE	246,673	3	0.56 (0.16-1.95)
Cyproterone 30 µg EE	131,097	1	0.33 (0.04-2.56)
Estradiol valerate, dienogest	6,176	0	-
<u>Non-oral</u>			
Patch	9,973	0	-
Vaginal ring	78,628	1	0.51 (0.07-3.96)
<u>Current or recent use of progestogen-only:</u>			
<u>Oral</u>			
Norethisterone	26,449	1	1.71 (0.22-13.30)
Levonorgestrel	261	0	-
Desogestrel	51,912	0	-
<u>Non-oral</u>			
MPA depot	15,865	0	-
Implant	36,337	0	-
LNG-IUS	66,195	2	1.46 (0.30-7.21)

\*Adjusted for: calendar year, parity, age, education, tubal sterilisation, hysterectomy, endometriosis, polycystic ovary syndrome and family history of breast or ovarian cancer.

†Ethinylestradiol

Table 3S. Relative risk of epithelial ovarian cancer in users of different types of hormonal contraception in women followed until first switch in hormonal contraception (i.e. “no change cohort”).

	Person-years	Cancer events	Adjusted* Relative Risk (95% confidence interval)
Never Use	8,150,250	566	1.00
Ever use (any hormonal contraception)	7,183,430	207	0.72 (0.61-0.86)
Former use (any hormonal)	2,590,322	126	0.86 (0.70-1.06)
Current or recent use (any hormonal)	4,593,109	81	0.58 (0.46-0.75)
<b>Current or recent use of combined hormonal contraception:</b>			
<b>Oral</b>			
Norethisterone 50µg EE†	36,494	3	1.47 (0.47-4.59)
Levonorgestrel 50µg EE	47,335	3	0.84 (0.27-2.62)
Norethisterone 30-35µg EE	116,090	3	0.93 (0.30-2.90)
Levonorgestrel 30-35 µg EE	519,113	7	0.30 (0.14-0.64)
Desogestrel 20-30 µg EE	988,952	9	0.38 (0.20-0.75)
Gestodene 20-35 µg EE	1,887,047	27	0.60 (0.40-0.89)
Drospirenone 20-35 µg EE	188,928	3	1.24 (0.39-3.91)
Norgestimate 35 µg EE	375,778	7	0.79 (0.37-1.67)
Cyproterone 30 µg EE	142,147	0	-
Estradiol valerate, dienogest	1,022	0	-
<b>Non-oral</b>			
Patch	2,253	0	-
Vaginal ring	11,729	0	-
<b>Current or recent use of progestogen-only contraception:</b>			
<b>Oral</b>			
Norethisterone	66,934	3	0.63 (0.20-1.96)
Levonorgestrel	6,972	1	1.57 (0.22-11.2)
Desogestrel	12,155	0	-
<b>Non-oral</b>			
MPA depot	7,321	3	9.54 (3.06-29.8)
Implant	10,575	0	-
LNG-IUS	172,265	12	0.71 (0.40-1.26)
<b>Duration of current or recent use of any hormonal contraception†</b>			
≤ 1 year	1,061,532	22	0.82 (0.53-1.27)
>1-≤5 years	2,313,446	38	0.63 (0.45-0.89)
>5-≤10 years	961,018	18	0.51 (0.31-0.82)
>10 years	257,112	3	0.18 (0.06-0.56)
<b>Time since last current use of any hormonal contraception‡</b>			
>1-≤5 years	1,280,405	43	0.73 (0.54-1.01)
>5-≤10 years	827,350	50	0.99 (0.73-1.34)
>10 years	482,566	33	0.90 (0.61-1.31)

\*Adjusted for: calendar year, parity, age, education, tubal sterilisation, hysterectomy, endometriosis, polycystic ovary syndrome and family history of breast or ovarian cancer.

†Ethinylestradiol

Table 4S. Age at diagnosis of ovarian cancer and FIGO stage (full cohort).

Age at diagnosis (years)	All tumours by FIGO stage*					Total n (%)
	I n (%)	II n (%)	III n (%)	IV n (%)	Unknown n (%)	
<20	20 (64.5)	5 (16.1)	0 (0)	2 (6.4)	4 (12.9)	31 (100.0)
20-29	49 (47.1)	10 (9.6)	18 (17.3)	13 (12.5)	14 (13.5)	104 (100.0)
30-39	92 (40.9)	29 (12.9)	42 (18.7)	38 (16.9)	24 (10.7)	225 (100.0)
40+	249 (28.0)	137 (15.4)	232 (26.1)	193 (21.7)	78 (8.8)	889 (100.0)
Total	410 (32.8)	181 (14.5)	292 (23.4)	246 (19.7)	120 (9.6)	1249 (100.0)

\*p-trend<0.001

Table 5S. Different histological types of ovarian cancer by FIGO stage at diagnosis (full cohort).

Histology	FIGO stage					Total cancer events n
	I n (%)	II n (%)	III n (%)	IV n (%)	Unknown n (%)	
Any epithelial	290 (32.1)	125 (13.8)	230 (25.5)	177 (19.6)	80 (8.9)	902
Clear cell	36 (59.0)	8 (13.1)	7 (11.5)	9 (14.7)	1 (1.6)	61
Endometriod	62 (45.9)	23 (17.0)	22 (16.3)	16 (11.8)	12 (8.9)	135
Mucinous	129 (63.2)	16 (7.8)	20 (9.8)	10 (4.9)	29 (14.2)	204
Serous	63 (12.5)	78 (15.5)	181 (36.1)	142 (28.3)	38 (7.6)	502
Non-epithelial	43 (58.9)	10 (13.7)	3 (4.1)	2 (2.7)	15 (20.5)	73
Malignant tumour not elsewhere specified	77 (28.1)	46 (16.8)	59 (21.5)	67 (24.4)	25 (9.1)	274